Elizabeth Yeu Lin

Elizabeth Yeu Lin, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Tarsus Pharmaceuticals, Inc. and Staar Surgical Co. The record holds 23 filings, for trades running from 16 June 2022 to 4 September 2026.

In open-market terms, that means 4 purchases worth €537k on one side and 12 sales worth €2.1M on the other. The net balance comes to €1.5M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant and 6 option exercises. So far in 2026, the count stands at no purchases and 10 sales.

Half of the purchases are above €125k and half below. On 1 out of 4 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 9 September 2026 came the latest disclosure, an open-market sale for €394k in Tarsus Pharmaceuticals, Inc. The most recent open-market purchase was published on 22 September 2023, 1,143 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.